Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections

Inclusion Criteria: * Informed consent obtained * Positive COVID-19 test * Must be receiving medical care in an intensive care nursing situation * Non-pregnant females * Intent to deliver full supportive care through aggressive management utilizing all available therapies for a minimum of 96 hours. * Platelet count \>30,000/mm3 at Screening * Clinical diagnosis of AKI requiring CRRT or ARDS Exclusion Criteria: * Cardiovascular instability that precludes initiation of continuous renal replacement therapy (CRRT). * Irreversible brain damage based on available historical and clinical information. * Presence of any solid organ transplant at any time. * Patients with stem cell transplant in the previous 100 days or who have not engrafted. * Acute or chronic use of circulatory support device other than ECMO such as LVADs, RVADs, BIVADs. * Metastatic malignancy which is actively being treated or may be treated with chemotherapy or radiation during the subsequent three month period after study treatment. * Chronic immunosuppression defined as \>20 mg prednisone qd alone without other immunosuppressant medications (ie (cyclophosphamide, azathioprine, methotrexate, rituximab, mycophenolate, cyclosporine). * Patient is moribund or chronically debilitated for whom full supportive care is not indicated. * Concurrent enrollment in another interventional clinical trial. Patients enrolled in observational studies (NO TEST DEVICE OR DRUG USED) are allowed to participate. * Any reason the Investigator deems exclusionary.